About Inari Medical
Inari Medical, Inc. is a privately held venture backed medical device company dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism. Inari is focused on solutions that enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs. Inari has developed two novel mechanical thrombectomy technology platforms. The FlowTriever System has FDA clearance for the treatment of pulmonary embolism and for thrombectomy in the peripheral vessels. The ClotTriever System has FDA clearance for thrombectomy in the peripheral vessels. Inari was founded in 2013 as a spin-out of Inceptus Medical, a medical device incubator. The company is backed by Gilde Healthcare (www.gildehealthcare.com), Versant Ventures (www.versantventures.com) and U.S. Venture Partners (www.usvp.com).
Bill Hoffman, Chief Executive Officer
Bill has focused on early stage companies with novel devices in new markets. Prior to Inari Medical, Bill served as CEO of Visualase, Inc., which developed and sold lasers for minimally invasive neurosurgery. The company was acquired by Medtronic for $105M in July, 2014, having raised less than $10m in equity funding. Prior to Visualase, Bill was Vice President of Sales at FoxHollow, Inc., helping to build a commercial team and revenue ramp that led to a successful IPO in 2004 and an acquisition by EV3 in 2007. Bill’s first early stage med tech experience was as head of sales at RITA Medical Systems, an interventional oncology company that enjoyed a successful IPO in 2000. He spent the early part of his career in various sales roles at Ethicon and Medtronic.
Drew Hykes, Chief Commercial Officer
Drew is a proven medical device operating executive with broad functional, geographic and sector experience. From 2012-2016 Drew served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market. Sequent was acquired by Terumo Corporation in July 2016 for $380 million. Prior to Sequent, Drew spent 11 years at Medtronic. His roles at Medtronic included the VP of Marketing for the AF Solutions business, VP of Clinical and Regulatory for the AF Solutions business and Director of Investor Relations. Drew also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. He earned a B.B.A. in Finance from the University of Wisconsin and an MBA from Harvard Business School.
Mitch Hill, Chief Financial Officer
Mitch has extensive experience leading financial functions at both large and small companies. With senior executive experience at a number of private equity and venture capital-backed companies in medical device and health care services, Mitch has led many organizations to scale their financial strategies during rapid growth, such as Cameron Health which was acquired by BSX and Visiogen which was acquired by ABT. Prior to entering the health care industry, served as CFO of Walt Disney Imagineering and as President and CFO of Buy.com, Inc., including at the time of its initial public offering in February 2000. Mitch brings a wealth of financial knowledge and experience from high growth industries and an understanding of the challenges and landscape of modern healthcare. He earned a BS in Accounting from Brigham Young Univ. and an MBA from Harvard Business School.
Dr. Tom Tu, Chief Medical Officer
Dr. Thomas Tu joins Inari Medical after practicing Interventional Cardiology for 16 years. He is a graduate of Harvard Medical School and completed residency at Massachusetts General Hospital. He was trained in Interventional Cardiology, Peripheral Vascular Intervention, and Structural Heart Disease at Beth Israel Deaconess Medical Center. Most recently, he was the Cath Lab director and leader of the Pulmonary Embolism, complex PCI, and TAVR programs at Baptist Health Louisville. Dr. Tu helped develop the early phase technology that allowed Inari Medical to optimize patient outcomes. He also served as the presenter for the FLARE IDE trial of the Inari FlowTriever Retrieval/Aspiration System. This study led to FDA 510 (k) clearance for treatment of pulmonary embolism, the first thrombectomy device cleared for that indication.
Paul Koehn, Vice President of Operations
Paul brings to Inari over 25 years of experience in high volume, high quality growth operations across multiple industries. With experience both in domestic and global strategic planning, Paul’s work in product development and production has resulted in 4 revolutionary device platforms and 150 total products. Paul has a excellent track record in overall business performance exceeding 80% gross margin on all products, 92% gross margin on devices, and established scalable production and distribution capacity to greater than 4 times demand. In addition, Paul also brings a understanding of construction of manufacturing facilities and corporate offices. Paul was most recently the Senior Vice President of Quality and Operations at Cardiovascular Systems Inc. where he was crucial in the growth of the company from $0 revenue in 2007 to over $200M in 2017.
Tara Dunn, Vice President of Clinical Affairs and Market Development
Tara has extensive multi-functional medical device experience across a range of start-ups and larger organizations. Her most recent role was as the Venous Business Segment Leader at Volcano Corporation, acquired by Philips in 2015. Tara’s venous business experienced explosive triple digit growth in her time at the helm. Prior to Philips Volcano, she worked at Medtronic in Corporate Development where she participated in numerous transactions including the ~$816M acquisition of Kanghui Holdings in China and the divestiture of its Physio-Control business unit to Bain Capital for $487M. Tara also worked as a project leader at a healthcare strategy consulting firm called Health Advances and as Manager, Clinical and Regulatory Affairs at InfraReDx. She earned an A.B. in Biology from Harvard University, a M.S. in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and a M.B.A from Harvard Business School. Tara was a member of the National Championship winning ice hockey team and Ivy league championship team in softball while at Harvard. She also went on to compete in the National Women’s Hockey League (NWHL) for two seasons.
John Borrell, Vice President of Sales
John brings over 25 years of extensive commercial experience with early stage and mature medical device companies. His most recent roles were VP of Global Sales and Marketing at Trireme Medical and Area VP of Sales at Medtronic/Covidien Venous Vascular. Prior to that he was VP of Sales and Marketing at Cardiovascular Systems Inc. (CSI), where he created/executed the commercial strategy driving revenue growth from $5M to $43M in year 1 of commercial launch. Prior to CSI, John was the US Director of Sales at Fox Hollow Technologies where he played an integral role in the aggressive revenue ramp in their early commercial years. Other successful start up’s that he was a part of prior to Fox Hollow: Novoste Corporation, Arterial Vascular Engineering and Heartport Inc. John earned his Bachelor of Science in Business Marketing from the University of Massachusetts at Lowell where he played Division 1 college hockey for four years.
Brian Strauss, Vice President of Engineering
Brian joined Inari in April 2017. Brian has an extensive background in development of novel and disruptive medical device technologies in early stage companies, consistently resulting in value creation and successful exits. He has held senior executive positions in R&D, operations, and IP development. Prior to joining Inari, Brian was Chief Technology Officer at Reverse Medical, Inc. where he was responsible for developing neurovascular catheters and devices, one of which was sold to Covidien in 2012 for $50m, the others of which were sold to Medtronic as part of their acquisition of Reverse in 2014 for $150m. Brian remained at Medtronic as R&D Director of their neurovascular division responsible for embolization product development. Before Reverse Medical, Brian held management and engineering positions at ev3 (acquired by Covidien), Micro Therapeutics (acquired by ev3), and Gish Biomedical (acquired by Sorin Medical). Brian holds a B.S. in mechanical engineering from the University of California, Santa Barbara, and a Masters of Business Administration from California State University, Long Beach. Brian is a named inventor on over 50 issued U.S. and international patents.
Eben Gordon, Vice President of Quality Assurance & Regulatory Affairs
Eben has extensive experience in medical device quality systems management and regulatory affairs and he joined Inari in June 2014. Prior to Inari, Eben held management positions at a number of medical device companies including, Senior Director, Regulatory Affairs At Sotera Wireless from December 2010 through June 2014. From March 2006 to August 2010, Eben served as Vice President, Regulatory Affairs and Quality Assurance at SenoRx. From May 2005 to March 2006, he was Vice President, Regulatory Affairs and Quality Assurance at ReVision Optics, a manufacturer of ophthalmic devices. From November 2001 to May 2005, Eben held various positions at Endocare, a manufacturer of devices for the treatment of urological conditions, including Vice President, Regulatory Affairs and Quality Assurance and Senior Director, Regulatory Affairs. From November 1996 to November 2001, Eben held various positions at Micro Therapeutics, including Director, Regulatory Affairs and Quality Assurance. He earned his B.S. in Zoology at California Polytechnic University.
Bob Rosenbluth, Ph.D., Chairman and Co-Founder
Bob has an extensive background of leadership, innovation, and entrepreneurship in the medical device industry. Bob served as President & CEO during the incubation and formation of Inari. Bob is one of the co-founders of Inceptus Medical, a medical device incubator founded in June 2011 and serves as Chairman, President and CEO. Prior to Inceptus, he was a founder of Sequent Medical. Bob served as President & CEO of Sequent from inception to 2010 and remains Chairman of the Board. Sequent was acquired by Terumo Medical Corporation for $380M. Before Sequent, Bob was a founder of MicroVention, serving as President and CEO since its inception in 1997 through September 2002 and as Chairman of the Board from inception through March 2006. MicroVention was acquired by Terumo in 2006. Prior to founding MicroVention, he founded Advanced Surgical Intervention and served in various business development and senior management positions at Medtronic, Pfizer, and Cardiothoracic Systems. He holds a B.S. in chemical engineering from Columbia University, an M.S. in chemical engineering, and a Ph.D. in mechanical engineering from UC Berkeley.
Brian Cox, Vice President & Co-Founder
Brian is a principal and one of the co-founders of Inceptus Medical, a medical device incubator founded in June 2011. Prior to Inceptus, he was a founder of Sequent Medical. Brian served as Vice President and Chief Technical Officer since the Company’s founding. During this time, Brian led the Sequent team in developing the Company’s initial technology platform from incubator to concept, through preclinical testing, and on to successful initial human use and CE mark. Sequent was acquired by Terumo Medical Corporation for $380M. Prior to Sequent, Brian was a founder of MicroVention which was acquired by Terumo in 2006. At MicroVention, Brian served as Vice President of Business and Technology Development. Prior to MicroVention, Brian was Engineering Manager at AneuRx, Inc. which was acquired by Medtronic in 1996. Prior to AneuRx, he held various managerial and technical positions with Advanced Surgical Intervention, Inc., Allergan Medical Optics, and Shiley/Pfizer. He earned a B.S. in mechanical engineering from Oregon State University and a M.B.A. from Pepperdine University. Brian is an inventor on over 50 issued U.S. and international patents.
Paul Lubock, Vice President & Co-Founder
Paul is a Principal and one of the co-founders of Inceptus Medical, a medical device incubator founded in June 2011. Prior to Inceptus, he was a co-founder of SenoRx, established in January 1998 to develop and market instruments for the diagnosis and treatment of breast cancer, which was acquired by C.R. Bard in July 2010 for $213M. He served as Chief Technical Officer from October 1999 and Senior Vice President from April 2009 until his departure in April 2011. Paul also served on the Board of Directors from January 1998 to December 2001 and served as Chief Operating Officer from January 1998 to October 1999. Prior to January 1998, Paul was the co-founder and a Principal at Abacus Design & Development, a medical product development company, and the founder of Laparomed, a laparoscopic medical device company acquired by Advanced Surgical in 1994. Paul held various positions at Laparomed, including President, Vice President of Engineering and served on its Board of Directors. Previously he was VP of Engineering at Medstone and held engineering management roles at Shiley/Pfizer and Thoratec. Paul holds over 130 issued U.S. patents. He earned his B.A. in Applied Mechanics and Engineering Science from the University of California, San Diego and his M.S. in Mechanical Engineering from the University of California, Berkeley.
This virtual patent marking registry is made available to provide constructive notice of the patent rights of Inari Medical Inc. with respect to the company’s FlowTriever® Thrombectomy System, ClotTriever® Thrombectomy System and their components. It is intended to serve as notice under 35 U.S.C. § 287(a). This registry may not be all inclusive, but Inari endeavors to keep it up to date and accurate.
These products, and the use thereof, may be covered by one or more of the following U.S. and/or international patents: US 10,045,790, US 10,098,651, US 10,004,531, US 9,844,387, US 9,717,519, US 9,700,332, US 9,526,865, US 9,526,864, US 9,408,620, US 9,259,237, US 8,968,330, US 8,784,434
Other U.S. and international patents pending.